1. Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi. Issue 6 (31st August 2016) Authors: Csizmadia, Vilmos; Hales, Paul; Tsu, Christopher; Ma, Jingya; Chen, Jiejin; Shah, Pooja; Fleming, Paul; Senn, Joseph J.; Kadambi, Vivek J.; Dick, Larry; Wolenski, Francis S. Journal: Toxicology research Issue: Volume 5:Issue 6(2016:Nov.) Page Start: 1619 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi. Issue 6 (31st August 2016) Authors: Csizmadia, Vilmos; Hales, Paul; Tsu, Christopher; Ma, Jingya; Chen, Jiejin; Shah, Pooja; Fleming, Paul; Senn, Joseph J.; Kadambi, Vivek J.; Dick, Larry; Wolenski, Francis S. Journal: Toxicology research Issue: Volume 5:Issue 6(2016:Nov.) Page Start: 1619 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗